Didanosine
- Generic Name
- Didanosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N4O3
- CAS Number
- 69655-05-6
- Unique Ingredient Identifier
- K3GDH6OH08
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
- Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 740
- Registration Number
- NCT00001066
- Locations
- 🇺🇸
HRS Palm Beach County Public Health Unit, West Palm Beach, Florida, United States
🇺🇸Children's Hosp of Washington DC, Washington, District of Columbia, United States
🇺🇸Howard Univ Hosp, Washington, District of Columbia, United States
Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 55
- Registration Number
- NCT00007202
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Inc. (ARCA) AIEDRP CRS, Atlanta, Georgia, United States
🇺🇸Feinberg School of Medicine, HIV/ACTU AIEDRP CRS, Chicago, Illinois, United States
🇺🇸Rush Univ. Med. Ctr., Dept. of Infectious Disease AIEDRP CRS, Chicago, Illinois, United States
Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-08-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT00002035
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Albany Med College / AIDS Treatment Ctr, Albany, New York, United States
🇺🇸Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2014-04-17
- Target Recruit Count
- 1710
- Registration Number
- NCT00000922
- Locations
- 🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States
🇺🇸Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York, New York, United States
Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 280
- Registration Number
- NCT00000831
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina, United States
🇺🇸Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 256
- Registration Number
- NCT00000838
- Locations
- 🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸Santa Clara Valley Med. Ctr., San Jose, California, United States
🇺🇸San Mateo County AIDS Program, San Mateo, California, United States
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 30
- Registration Number
- NCT00000753
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 200
- Registration Number
- NCT00001063
- Locations
- 🇺🇸
Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States
A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 750
- Registration Number
- NCT00000671
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Hemophilia Ctr of Western PA / Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 116
- Registration Number
- NCT00000656
- Locations
- 🇺🇸
Univ of Washington, Seattle, Washington, United States
🇺🇸Palo Alto Veterans Adm Med Ctr / Stanford Univ, Palo Alto, California, United States
🇺🇸Whitman - Walker Clinic, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.